Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 7Genitourinary 1Gastrointestinal 1Dermatologic 1

Conditions

Ovarian Neoplasms 1Melanoma 1Kidney Neoplasms 1Colorectal Neoplasms 1

Interventions

pembrolizumab 28Cyclophosphamide 14Nivolumab 13Paclitaxel 7fludarabine 6Specimen Handling 5aldesleukin 4Taxes 4Ipilimumab 4Interleukin-2 4Gemcitabine 4Drug Therapy 4Docetaxel 4Carboplatin 4Bevacizumab 4poly ICLC 3liposomal doxorubicin 3epacadostat 3cobimetinib 3cemiplimab 3Magnetic Resonance Spectroscopy 3Injections 3Cisplatin 3veliparib 2ulixertinib 2sargramostim 2pertuzumab 2pegilodecakin 2pazopanib 2osimertinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Ovarian Neoplasms × trebananib × Dermatologic × Clear all
NCT03239145 2026-03-12

Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor

Dana-Farber Cancer Institute

Phase 1 Completed
62 enrolled 17 charts
DermatologicGastrointestinalGenitourinaryGynecologic

Kidney Neoplasms, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡